AC Immune SA (ACIU)

NASDAQ: ACIU · IEX Real-Time Price · USD
3.038
+0.008 (0.26%)
Mar 28, 2024, 10:52 AM EDT - Market open
0.26%
Market Cap 300.65M
Revenue (ttm) 17.62M
Net Income (ttm) -64.56M
Shares Out 99.20M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 32,883
Open 3.070
Previous Close 3.030
Day's Range 3.000 - 3.180
52-Week Range 1.780 - 5.140
Beta 1.03
Analysts Strong Buy
Price Target 16.00 (+426.66%)
Earnings Date Mar 14, 2024

About ACIU

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Ph... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 23, 2016
Employees 133
Stock Exchange NASDAQ
Ticker Symbol ACIU
Full Company Profile

Financial Performance

In 2023, AC Immune's revenue was 14.80 million, an increase of 276.14% compared to the previous year's 3.94 million. Losses were -54.23 million, -23.35% less than in 2022.

Financial numbers in CHF Financial Statements

Analyst Forecast

According to one analyst, the rating for ACIU stock is "Strong Buy" and the 12-month stock price forecast is $16.0.

Price Target
$16.0
(426.66% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2 ACI-7104.056 VacSYn Phase 2 trial in ...

14 days ago - GlobeNewsWire

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2024) Andrea Pfeifer, Ph.D., CEO to lea...

5 weeks ago - GlobeNewsWire

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company's strategy is focused on advancing the Phase 2 development of its three active immunotherapies Active immunotherapy now consider...

2 months ago - GlobeNewsWire

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases

3 months ago - GlobeNewsWire

AC Immune Announces Pricing of Underwritten Offering of Common Shares

AC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 – AC Immune SA (Nasdaq: ACIU) (the “Company” or “AC Immune”), a clinical-stage biopharmac...

3 months ago - GlobeNewsWire

AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial

AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of ACI-35.03...

3 months ago - GlobeNewsWire

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO Outstanding scientist and entrepreneur Dr. Madiha Derouazi appointed as new CSO Retiring CSO Dr. Marie ...

4 months ago - GlobeNewsWire

AC Immune to Present at the Jefferies 2023 London Healthcare Conference

AC Immune to Present at the Jefferies 2023 London Healthcare Conference Lausanne, Switzerland, November 7, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering pre...

5 months ago - GlobeNewsWire

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update Results from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE P...

5 months ago - GlobeNewsWire

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023

5 months ago - GlobeNewsWire

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference

AC Immune Announces Upcoming Presentations at the 16 th CTAD Conference

5 months ago - GlobeNewsWire

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 Lausanne, Switzerland, October 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneerin...

6 months ago - GlobeNewsWire

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

7 months ago - GlobeNewsWire

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

8 months ago - GlobeNewsWire

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023

AC Immune to Present at the B TIG Virtual Biotechnology Conference 2023

8 months ago - GlobeNewsWire

AC Immune SA Appoints New Chief Medical Officer

AC Immune SA Appoints New Chief Medical Officer Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee member Lausanne, Switzerland, July 2 6 , 202 3 – AC Immune SA (NASDAQ: ACI...

8 months ago - GlobeNewsWire

AC Immune Showcasing Precision Medicine Programs at AAIC 2023

AC Immune Showcas ing Precision Medicine P rograms at A AIC 202 3

9 months ago - GlobeNewsWire

AC Immune's stock soars 13% after FDA grants fast-track designation to Alzheimer's treatment

AC Immune SA's stock ACIU, +4.21% soared 13% premarket Tuesday, after the Swiss-based biotech said it has received U.S. Food and Drug Administration fast-track designation for an Alzheimer's disease t...

9 months ago - Market Watch

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer's Disease

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid- beta Active Immunotherapy , ACI-24.060, to Treat Alzheimer's Disease

9 months ago - GlobeNewsWire

AC Immune Holds Annual General Meeting of Shareholders

AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board of Directors Lausanne, Switzerland, June 23, 2023 – AC Immune SA (NASDAQ: ACIU), a...

9 months ago - GlobeNewsWire

AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update

AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimer's disease (AD)...

11 months ago - GlobeNewsWire

AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer's Disease

AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer's Disease

1 year ago - GlobeNewsWire

AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

AC Immune at AD/PD ™ 202 3 to Present New Clinical and Preclinical Data f rom its Precision Medicine Pipeline

1 year ago - GlobeNewsWire

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update

1 year ago - GlobeNewsWire